FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005275461> ?p ?o ?g. }

• W2005275461 endingPage "406" @default.
• W2005275461 startingPage "399" @default.
• W2005275461 abstract "Interleukin-11 is a mesenchymally derived cytokine with pleiotropic activities. A pilot study suggested therapeutic benefit of recombinant human interleukin-11 (rhIL-11) in patients with Crohn's disease.To determine the safety and preliminary estimate of efficacy of rhIL-11 in treating active Crohn's disease.Patients with mild to moderately active Crohn's disease, defined as a Crohn's disease activity index (CDAI) > or = 220 and < or = 450, were enrolled in a multicentre trial. Stable doses of 5-aminosalicylates, antibiotics, 6-mercaptopurine or azathioprine were permitted with appropriate wash-in periods. Oral, intravenous or rectally administered corticosteroids were not allowed. Patients were randomized to 6 weeks of subcutaneous injection with rhIL-11 15 microg/kg or placebo weekly, or rhIL-11 7.5 microg/kg or placebo twice weekly. The primary end-point was per cent change in CDAI at week 6; the major secondary end-point was the proportion of patients in remission, defined as a 100 point decrease in CDAI and absolute CDAI < or = 150.Baseline characteristics were similar among the 148 evaluated patients (49 placebo, 49 rhIL-11 15 microg/kg once weekly, 50 rhIL-11 7.5 microg/kg twice weekly). Treatment was well-tolerated, with mild injection site reactions occurring more frequently among patients treated with rhIL-11. Headache, oedema, and increased platelet count occurred significantly more often in the rhIL-11 7.5 microg/kg twice weekly group, but not the 15 microg/kg once weekly group. There was a trend toward decreased mean per cent change in CDAI in the rhIL-11 15 micro/kg once weekly group vs. placebo (-31.5% vs. -18.5%, 95% confidence interval for the difference -27.9-1.6%). A significantly greater proportion of patients receiving rhIL-11 15 microg/kg once weekly achieved remission compared to placebo (36.7% vs. 16.3%, 95% confidence interval for the difference 3.4-37.4%; 16.4% for rhIL-11 7.5 microg/kg, N.S.).Weekly subcutaneous injection with rhIL-11 15 microg/kg is safe and effective in inducing remission in a subset of patients with active Crohn's disease." @default.
• W2005275461 created "2016-06-24" @default.
• W2005275461 creator A5005220122 @default.
• W2005275461 creator A5012785273 @default.
• W2005275461 creator A5017140014 @default.
• W2005275461 creator A5017813712 @default.
• W2005275461 creator A5023224607 @default.
• W2005275461 creator A5043944880 @default.
• W2005275461 creator A5045691934 @default.
• W2005275461 creator A5054712915 @default.
• W2005275461 creator A5062218070 @default.
• W2005275461 date "2002-03-01" @default.
• W2005275461 modified "2023-10-14" @default.
• W2005275461 title "Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease" @default.
• W2005275461 cites W137557781 @default.
• W2005275461 cites W1594620939 @default.
• W2005275461 cites W1671682816 @default.
• W2005275461 cites W172996185 @default.
• W2005275461 cites W1850499851 @default.
• W2005275461 cites W1970455747 @default.
• W2005275461 cites W1983039678 @default.
• W2005275461 cites W1986337203 @default.
• W2005275461 cites W1996632586 @default.
• W2005275461 cites W1999460382 @default.
• W2005275461 cites W2002883352 @default.
• W2005275461 cites W2025171024 @default.
• W2005275461 cites W2028147079 @default.
• W2005275461 cites W2054373032 @default.
• W2005275461 cites W2090142426 @default.
• W2005275461 cites W2107677729 @default.
• W2005275461 cites W2146906769 @default.
• W2005275461 cites W2321453230 @default.
• W2005275461 cites W2342314812 @default.
• W2005275461 cites W3149527659 @default.
• W2005275461 cites W4211192296 @default.
• W2005275461 cites W4241511731 @default.
• W2005275461 cites W4246819101 @default.
• W2005275461 doi "https://doi.org/10.1046/j.1365-2036.2002.01179.x" @default.
• W2005275461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11876692" @default.
• W2005275461 hasPublicationYear "2002" @default.
• W2005275461 type Work @default.
• W2005275461 sameAs 2005275461 @default.
• W2005275461 citedByCount "132" @default.
• W2005275461 countsByYear W20052754612012 @default.
• W2005275461 countsByYear W20052754612013 @default.
• W2005275461 countsByYear W20052754612014 @default.
• W2005275461 countsByYear W20052754612015 @default.
• W2005275461 countsByYear W20052754612016 @default.
• W2005275461 countsByYear W20052754612017 @default.
• W2005275461 countsByYear W20052754612018 @default.
• W2005275461 countsByYear W20052754612019 @default.
• W2005275461 countsByYear W20052754612020 @default.
• W2005275461 countsByYear W20052754612021 @default.
• W2005275461 countsByYear W20052754612022 @default.
• W2005275461 countsByYear W20052754612023 @default.
• W2005275461 crossrefType "journal-article" @default.
• W2005275461 hasAuthorship W2005275461A5005220122 @default.
• W2005275461 hasAuthorship W2005275461A5012785273 @default.
• W2005275461 hasAuthorship W2005275461A5017140014 @default.
• W2005275461 hasAuthorship W2005275461A5017813712 @default.
• W2005275461 hasAuthorship W2005275461A5023224607 @default.
• W2005275461 hasAuthorship W2005275461A5043944880 @default.
• W2005275461 hasAuthorship W2005275461A5045691934 @default.
• W2005275461 hasAuthorship W2005275461A5054712915 @default.
• W2005275461 hasAuthorship W2005275461A5062218070 @default.
• W2005275461 hasBestOaLocation W20052754611 @default.
• W2005275461 hasConcept C126322002 @default.
• W2005275461 hasConcept C142724271 @default.
• W2005275461 hasConcept C168563851 @default.
• W2005275461 hasConcept C203092338 @default.
• W2005275461 hasConcept C204243189 @default.
• W2005275461 hasConcept C204787440 @default.
• W2005275461 hasConcept C27081682 @default.
• W2005275461 hasConcept C2776760755 @default.
• W2005275461 hasConcept C2779134260 @default.
• W2005275461 hasConcept C2779280984 @default.
• W2005275461 hasConcept C535046627 @default.
• W2005275461 hasConcept C71924100 @default.
• W2005275461 hasConcept C90924648 @default.
• W2005275461 hasConceptScore W2005275461C126322002 @default.
• W2005275461 hasConceptScore W2005275461C142724271 @default.
• W2005275461 hasConceptScore W2005275461C168563851 @default.
• W2005275461 hasConceptScore W2005275461C203092338 @default.
• W2005275461 hasConceptScore W2005275461C204243189 @default.
• W2005275461 hasConceptScore W2005275461C204787440 @default.
• W2005275461 hasConceptScore W2005275461C27081682 @default.
• W2005275461 hasConceptScore W2005275461C2776760755 @default.
• W2005275461 hasConceptScore W2005275461C2779134260 @default.
• W2005275461 hasConceptScore W2005275461C2779280984 @default.
• W2005275461 hasConceptScore W2005275461C535046627 @default.
• W2005275461 hasConceptScore W2005275461C71924100 @default.
• W2005275461 hasConceptScore W2005275461C90924648 @default.
• W2005275461 hasIssue "3" @default.
• W2005275461 hasLocation W20052754611 @default.
• W2005275461 hasLocation W20052754612 @default.
• W2005275461 hasOpenAccess W2005275461 @default.
• W2005275461 hasPrimaryLocation W20052754611 @default.
• W2005275461 hasRelatedWork W1976879156 @default.

• next